DNDi and Atomwise collaborate to advance drug development using AI for neglected diseases

Geneva, Switzerland and San Francisco, USA – 16 April 2019
Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development
Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and DNDi, a not-for-profit research and development organization working to deliver new treatments for neglected diseases, today announced that promising drug-like compounds have been discovered in a programme to develop first-in-class treatments for Chagas disease. The research collaboration is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards programme.

Chagas disease: the time is now to end 110 years of neglect

Rio de Janeiro – 11 April 2019
The people affected by Chagas disease will claim this 14th of April as World Chagas Day in the hope of increasing global awareness, building on the progress already made against this disease, which has been neglected for more than a century
The International Federation of Associations of People Affected by Chagas disease (FINDECHAGAS) has launched an online petition through the platform change.org in support of the official declaration of April 14th as their World Day. This proposal will be tabled at the 72nd World Health Assembly, to be held in Geneva at the end of May 2019. The particular date has been chosen because on that same day, 110 years ago, the Brazilian doctor Carlos Chagas confirmed the first case of the disease in a child, called Berenice Soares.

GARDP set up as independent legal entity

Geneva, Switzerland – 2 April 2019
Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR
GARDP is now an independent legal entity following a successful three-year incubation, hosted by DNDi. During this time, GARDP has already begun working with partners to develop antibiotics to tackle drug-resistant infections which pose a threat to global health and development, including the achievement of the Sustainable Development Goals.

Study shows dramatically shorter treatment for Chagas disease could be just as effective, and significantly safer

Barcelona/Rio de Janeiro – 14 March 2019
Results could help remove one of the barriers to treatment scale up and bring new hope for people with Chagas disease
A two-week treatment course for adult patients with chronic Chagas disease showed, when compared to placebo, similar efficacy and significantly fewer side effects than the standard treatment duration of eight weeks, according to the results of a clinical trial in Bolivia led by DNDi.

Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis

London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.

Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo

Paris/Geneva – 30 January 2019
Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis, more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC). This approval paves the way for the distribution of fexinidazole in endemic countries this year, with another submission planned in Uganda.

Drugs for Neglected Diseases initiative and The BMJ launch a special collection on neglected diseases and innovation in South Asia

New Delhi- 23 January 2019
Research and policy Innovation is vital for sustained control & elimination of neglected diseases in South Asia
DNDi has launched a special collection of articles entitles ‘Neglected Diseases and Innovation in South Asia’ published today by The BMJ. The collection brings together over 30 authors from across South Asia and internationally, to identify research priorities and recommendations for action to improve the health of neglected patients in the region. The collection maps progress in the control or elimination of neglected diseases such as lymphatic filariasis, kala-azar, and snakebites in the region, and highlights the growing challenge of antimicrobial resistance.

Combination therapy found to be more effective in treating patients with leishmaniasis and HIV

Geneva/Nairobi – 17 January 2019
The results of clinical trials conducted in Ethiopia by DNDi, in partnership with Médecins Sans Frontières, the University of Gondar, and Addis Ababa University, open the way for more effective and safer treatments for people with both HIV and visceral leishmaniasis, a group of patients who have historically suffered from poor treatment options. The results were published today in PLOS Neglected Tropical Diseases.